Investment Summary

Athyrium Capital Management Invests In Centinel Spine

On December 1, 2017, asset manager Athyrium Capital Management invested in medical products company Centinel Spine

Investment Highlights
  • This is Athyrium Capital Management’s 5th transaction in the Medical Products sector.
  • This is Athyrium Capital Management’s 24th transaction in the United States.
  • This is Athyrium Capital Management’s 3rd transaction in Pennsylvania.

Investment Summary
Date 2017-12-01
Target Centinel Spine
Sector Medical Products
Investor(s) Athyrium Capital Management
Deal Type Growth Capital

Target

Centinel Spine

West Chester, Pennsylvania, United States
Centinel Spine is a privately-held spine company focused on anterior column reconstruction. The company offers a continuum of trusted, brand-name, motion-preserving and fusion solutions providing the most robust and clinically-proven technology platforms in the world for total disc replacement (prodisc®) and Integrated Interbody™ fusion (STALIF®). Centinel Spine is based in West Chester, Pennsylvania.

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Investor(S) 1

Investor

Athyrium Capital Management

Investor Investor Investor Investor Investor

Category Asset Manager
Founded 2008
PE ASSETS 3.7B USD
Size Large
Type Sector Focused
DESCRIPTION

Athyrium Capital Management is a large asset manager focused on the healthcare sector. Athyrium invests in a wide range of financial instruments including royalties, structured credit, and equities as well as select special situations. Athyrium Capital was established in 2008 and is headquartered in New York City.

DEAL STATS #
Overall 26 of 44
Sector (Medical Products) 5 of 6
Type (Growth Capital) 4 of 10
State (Pennsylvania) 3 of 4
Country (United States) 24 of 39
Year (2017) 7 of 7
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2017-11-07 Biora Therapeutics

San Diego, California, United States

Progenity helps patients and their families Prepare for Life, with medically relevant health information starting before conception, through pregnancy and adulthood. Using our highly-complex molecular diagnostic testing, healthcare providers can access the most advanced genomic technology to guide patient care at critical life stages. Progenity was founded in 2010 and is based in San Diego, California.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2018-01-02 OptiNose

Yardley, Pennsylvania, United States

OptiNose is a specialty pharmaceutical company focused on the development and commercialization of products for patients cared for by, or in consultation with, ear, nose, and throat (ENT) or allergy specialists. OptiNose was founded in 2000 and is based in Yardley, Pennsylvania.

Buy -
Mergr

Product

Company

Legal